The COHCCC Director has a wide array of advisory input to assist in planning for the Center's future and evaluating the outcomes of Center programs and policy implementation. The most important of these is the day-to-day decision-making body, the Cancer Center Executive Committee. This group consists of the traditional senior leaders of the Center, the Deputy Directors and Associate Directors, as well as several other key senior members of the Center. All plans either originate in or pass through this group. Our External Advisory Board continues to play a significant role in reviewing our plans and advising on our course of action. Our senior leaders. Program Leaders and Core Directors convene in the Cancer Center Leadership Council. The Core Facilities Oversight Committee reviews all Shared Resources activities and services to assure compliance and efficiency. Our Clinical Trials Minority Recruitment Committee is charged with increasing minority enrollment in clinical trials. Our ongoing full Cancer Center retreats and our individual Program retreats are key for promoting and facilitating key collaborations. Strategic planning is a dynamic process that is informally woven into the structure of each of our senior committees, both internal and external. In addition, COHCCC engages in a formal strategic planning process. Key leadership, including the Cancer Center Director and COH Chief Strategy Officer, meet to outline an appropriate process for the development of the objectives and an approach for the CCC strategy document. The approach includes data collection and analysis, multiple interviews with key CCC stakeholders, and an iterative review and approval process of the final deliverable. By design, the plan outlines specific objectives and goals and drives the future direction of the CCC while supporting its mission, vision and aspirations. Performance and progress of the stated goals within the plan are tracked and catalogued on an ongoing basis. Funding is requested for a small portion of the costs for our annual External Advisory Board meeting. Cancer Center retreat and Program retreats.

Public Health Relevance

Ongoing Planning and Evaluation is essential for charting the course of the Cancer Center. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Salhotra, A; Tsai, N; Thomas, S H et al. (2015) Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50:139-41
Ali, H; Palmer, J; Eroglu, Z et al. (2015) Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplant 50:307-9
Behrendt, Carolyn E; Hurria, Arti; Tumyan, Lusine et al. (2014) Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer. J Natl Compr Canc Netw 12:1579-85
Yang, Lixin; Perez, Aldwin Apollo; Fujie, Sayuri et al. (2014) Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 14:124
Gillis, Peter A; Hernandez-Alvarado, Nelmary; Gnanandarajah, Josephine S et al. (2014) Development of a novel, guinea pig-specific IFN-? ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. Vaccine 32:3963-70
Chen, Shiuan; Zhou, Dujin; Hsin, Li-Yu et al. (2014) AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci 139:198-209
Bhatia, Smita; Landier, Wendy; Hageman, Lindsey et al. (2014) 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 124:2345-53
Sun, Virginia; Grant, Marcia; McMullen, Carmit K et al. (2014) From diagnosis through survivorship: health-care experiences of colorectal cancer survivors with ostomies. Support Care Cancer 22:1563-70

Showing the most recent 10 out of 912 publications